UnicoCell Biomed Co., Ltd.
UnicoCell Biomed Co., Ltd. engages in the research and development of stem cell drugs in Taiwan and Japan. The company develops ELIXCYTE for the treatment of knee osteoarthritis and chronic kidney disease. It also operates an allogeneic adipose stem cell bank. In addition, the company offers autologous stem cell therapy; conditioned medium; CDMO; UnicoVial, a cryogenic vial for the storage of cel… Read more
UnicoCell Biomed Co., Ltd. (6794) - Total Liabilities
Latest total liabilities as of June 2025: NT$81.69 Million TWD
Based on the latest financial reports, UnicoCell Biomed Co., Ltd. (6794) has total liabilities worth NT$81.69 Million TWD as of June 2025.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
UnicoCell Biomed Co., Ltd. - Total Liabilities Trend (2017–2024)
This chart illustrates how UnicoCell Biomed Co., Ltd.'s total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
UnicoCell Biomed Co., Ltd. Competitors by Total Liabilities
The table below lists competitors of UnicoCell Biomed Co., Ltd. ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Betmakers Technology Group Ltd
PINK:TPBTF
|
USA | $38.93 Million |
|
Korea Parts & Fasteners Co.Ltd
KQ:024880
|
Korea | ₩356.28 Billion |
|
Alpha Technology Group Limited Ordinary Shares
NASDAQ:ATGL
|
USA | $10.33 Million |
|
Zenix Robotics Co.,Ltd
KQ:381620
|
Korea | ₩10.03 Billion |
|
Insights Analytics Bhd
KLSE:0376
|
Malaysia | RM43.67 Million |
|
Global View Co Ltd
TW:3040
|
Taiwan | NT$574.45 Million |
|
Big Shopping Centers Ltd
TA:BIG
|
Israel | ILA29.96 Billion |
|
Tamil Nadu Newsprint & Papers Limited
NSE:TNPL
|
India | ₹40.47 Billion |
Liability Composition Analysis (2017–2024)
This chart breaks down UnicoCell Biomed Co., Ltd.'s total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 35.10 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.11 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.10 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how UnicoCell Biomed Co., Ltd.'s debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for UnicoCell Biomed Co., Ltd. (2017–2024)
The table below shows the annual total liabilities of UnicoCell Biomed Co., Ltd. from 2017 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | NT$93.28 Million | +4.24% |
| 2023-12-31 | NT$89.49 Million | +11.22% |
| 2022-12-31 | NT$80.46 Million | +131.81% |
| 2021-12-31 | NT$34.71 Million | -27.41% |
| 2020-12-31 | NT$47.81 Million | -22.70% |
| 2019-12-31 | NT$61.86 Million | +373.23% |
| 2018-12-31 | NT$13.07 Million | +214.36% |
| 2017-12-31 | NT$4.16 Million | -- |